Mean ± SD (n = 15) | Min – max (n = 15) | |
---|---|---|
Gender (n male/women) | 12/3 | |
Age (yr) | 67 ± 7 | 58–78 |
Weight (kg) | 81 ± 15 | 51–109 |
Height (cm) | 176 ± 9 | 158–188 |
BMI | 26 ± 4 | 19–37 |
BSA | 2.0 ± 0.2 | 1.5–2.3 |
NYHA classification n (%) | ||
Class II | 7 (47) | |
Class III | 5 (33) | |
Class IV | 3 (20) | |
Echocardiography | ||
LVEF (%) | 31 ± 11 | 17–53 |
RV dysfunction | ||
TAPSE < 16 mm (n) | 4/15 | |
Pulmonary hypertension | ||
TR velocity > 2.8 m/s (n) | 2/15 | |
Electrocardiogram | ||
Heart rate | 72 ± 17 | 50–110 |
QRS duration (ms) | 151 ± 27 | 118–194 |
IVMD (ms) in 13 patients | 42 ± 14 | 20–60 |
SPWMD (ms) in 11 patients | 152 ± 70 | 10–240 |
Comorbidities n (%) | ||
Hypertension | 5 (33) | |
Coronary artery disease | 11 (73) | |
Congestive heart failure | 14 (93) | |
COPD | 6 (40) | |
Diabetes mellitus | 3 (20) | |
Medication n (%) | ||
Beta-blocker | 12 (80) | |
ACE inhibitors | 11 (73) | |
AT II blockers | 2 (13) | |
Loop diuretics | 12 (80) | |
K-sparing agents | 6 (40) | |
Statins | 14 (93) | |
Laboratory | ||
Creatinine (μmol/L) | 105 ± 28 | 31–160 |
NT-proBNP (pmol/L) | 162 ± 111 | 36–440 |